Data from a Phase 1b Study of Quemliclustat-Based Regimens Showed Promising Overall Survival in Treatment-Naïve Metastatic Pancreatic Cancer
HAYWARD, Calif.--(BUSINESS WIRE)--Jan 16, 2024--
Source: eagletribune.com
Stay updated with breaking news from All Pooled. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
HAYWARD, Calif.--(BUSINESS WIRE)--Jan 16, 2024--
Median Overall Survival was 15.7 months for all patients treated with 100 mg quemliclustat-based regimens in the ARC-8 study, which exceeds the historical benchmark data for chemotherapy alone A...